Please login to the form below

Not currently logged in
Email:
Password:

NPS

This page shows the latest NPS news and features for those working in and with pharma, biotech and healthcare.

Merck’s backing of NGM Bio yields NASH drug deal

Merck’s backing of NGM Bio yields NASH drug deal

The lead NASH candidate at that time was NP 201, but seems to have been leapfrogged by NGM313, now renamed MK-3655.

Latest news

More from news
Approximately 3 fully matching, plus 17 partially matching documents found.

Latest Intelligence

  • Biotech profile: Tom Evans, CEO, Vaccitech.

    As many of the safety and manufacturing issues surrounding our MVA-NP M1 vaccine are already de-risked, a positive efficacy readout in the challenge study should allow us to take

  • Digital mania - a question of value Digital mania - a question of value

    So bad in fact, that the best Net Promoter Score (NPS) is a whopping -40% (minus!).

  • A rare talent A rare talent

    $6bn deal that was completed in January 2016. Before that the firm had a busy 2015, buying US rare disease-focused biotech NPS Pharma for $5.2bn and rare disease and

  • Deal Watch table for January 2015 Deal Watch table for January 2015

    NPS/Shire. NPS specialises in rare diseases including Gattex [teduglutide] for the treatment of short bowel syndrome.

  • Pharma deals during January 2015 Pharma deals during January 2015

    Top of the table was the all cash acquisition of NPS Pharmaceuticals by Shire for a total of $5.2bn just one year on from its acquisition of ViroPharma.

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

Latest appointments

  • Prevail Therapeutics adds to its board of directors Prevail Therapeutics adds to its board of directors

    From 2008-2015 Nader was president and chief executive officer of NPS Pharma, until Shire acquired the company for $5.2bn. ... Before his time at NPS, Nader was a venture partner at Care Capital and he also previously served on the North America

  • CRISPR Therapeutics appoints Dr Tony Coles CRISPR Therapeutics appoints Dr Tony Coles

    He has also previously held executive and leadership positions at NPS Pharmaceuticals, Vertex Pharmaceuticals, Bristol-Myers Squibb and Merck &Co.

  • Patrick Fabbio named CFO at electroCore Patrick Fabbio named CFO at electroCore

    He joins from NPS Pharmaceuticals where he was VP finance. US-based electroceutical healthcare company electroCore has named Patrick Fabbio as chief financial officer. ... Fabbio has over 20 years of financial leadership experience in public and private

More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

Report: Customer experience, shaping digital healthcare
In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
Biomarker
Encouraging signs in biomarker R&D
The cancer immunotherapy firms ramping-up biomarker R&D...
Programmatic methodology and why you should be using it
What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...

Infographics